相关实验视频
Updated: Jun 20, 2025

10:55
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
2.1K
UBE2D1通过调节p21无处置化,促进质母细胞瘤的扩散
Yongfeng Wang1, Qianquan Ma2, Haoyu Li3,4
1Department of Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Key Clinical Laboratory of Henan Province, Zhengzhou, China.
Molecular carcinogenesis
|July 17, 2024
概括
乌比奎丁结合酶E2D1 (UBE2D1) 驱动着质母细胞瘤 (GBM) 的生长和不良预后. 抑制UBE2D1可以阻止GBM细胞的增殖,并为这种侵袭性脑癌提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 质母细胞瘤 (GBM) 是一种具有侵略性的脑瘤,其特征是无法控制的细胞增殖和耐治疗性.
- 驱动GBM恶性瘤的潜在分子机制仍然不完全理解.
- 鉴定GBM生长的新型调节剂对于开发有效治疗方法至关重要.
研究的目的:
- 为了确定参与质母细胞瘤发展的关键分子参与者.
- 调查泛素结合酶E2D1 (UBE2D1) 在GBM病变发生过程中的作用.
- 阐明UBE2D1影响GBM细胞周期进展的机制.
主要方法:
- 在GBM组织中对UBE2D1表达的定量分析.
- 评估UBE2D1水平与患者预后之间的相关性.
- 在GBM细胞系中对UBE2D1表达的实验操纵 (敲击).
- 细胞循环分析 (G1停止) 和蛋白质降解研究.
主要成果:
- 在GBM中,UBE2D1显著过度表达,并与患者的不良结果有关.
- 抑制UBE2D1可以抑制GBM细胞的增殖,并诱导G1细胞循环停止.
- 通过UBCH5A和STUB1,UBE2D1促进细胞循环抑制剂p21的泛化和降解.
结论:
- UBE2D1是质母细胞瘤中关键的致癌驱动因素.
- UBE2D1通过降低细胞循环抑制剂p21的调节来促进GBM的生长.
- 准UBE2D1是一个有希望的治疗策略,可以改善质母细胞瘤的预后.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

